Original research articleEssential difference between the pharmacological spectrum of (−)-deprenyl and Rasagiline (cas 136236-51-6)
-
Add time:09/01/2019 Source:sciencedirect.com
Background(−)-Deprenyl and rasagiline are classified as selective inhibitors of B-type MAO. The DATATOP study revealed that the administration of (−)-deprenyl to untreated patients with Parkinson's disease (PD) significantly delays the need for levodopa therapy (Parkinson Study Group, 1989). Rasagiline was ineffective in this respect (Parkinson Study Group, 2002). The aim of this paper is to explain the reasoning behind the differentiation between (−)-deprenyl and rasagiline.
We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers
Prev:Case ReportRasagiline (cas 136236-51-6) induced hypersexuality in Parkinson’s disease
Next:Chemoenzymatic synthesis of Rasagiline (cas 136236-51-6) mesylate using lipases) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular articleEffect of long-term treatment with Rasagiline (cas 136236-51-6) on cognitive deficits and related molecular cascades in aged mice09/07/2019
- Research ReportRasagiline (cas 136236-51-6) prevents neurodegeneration in thiamine deficient rats—A longitudinal MRI study09/06/2019
- Rasagiline (cas 136236-51-6) in Parkinson's Disease09/05/2019
- Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study09/04/2019
- Protective effect of Rasagiline (cas 136236-51-6) in aminoglycoside ototoxicity09/03/2019
- Chemoenzymatic synthesis of Rasagiline (cas 136236-51-6) mesylate using lipases09/02/2019
- Case ReportRasagiline (cas 136236-51-6) induced hypersexuality in Parkinson’s disease08/31/2019
- Data articleSynthesis and characterization of 1-pyrindane derivatives as Rasagiline (cas 136236-51-6) analogues08/30/2019
- Rasagiline (cas 136236-51-6) monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan08/29/2019
